Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00070993 · ClinicalTrials.gov registry record · Phase 2
Creatine for the Treatment of Amyotrophic Lateral Sclerosis
A Phase 2 study, sponsored by National Center for Complementary and Integrative Health (NCCIH).
- Completed
- Registry status
- Phase 2
- Development phase
- 110
- Enrollment target
NCT00070993 is a Phase 2 study that has completed, run by National Center for Complementary and Integrative Health (NCCIH). The registered enrollment target is 110 participants.
The verdict
NCT00070993, a Phase 2 study, has completed, sponsored by National Center for Complementary and Integrative Health (NCCIH).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 110 participants
- Enrollment target
Study Summary
Creatine is a naturally occurring chemical involved in the production of energy in muscle. Abnormalities in creatine have been linked to the progression of degenerative neuromuscular diseases such as amyotrophic lateral sclerosis (ALS, or Lou Gehrig's Disease). This study will test whether taking creatine can improve the symptoms of ALS.
Interventions
- DRUG creatine monohydrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2002-12 |
| Est. Completion | 2006-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00070993
The ClinicalTrials.gov registry entry for NCT00070993 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 110 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Center for Complementary and Integrative Health (NCCIH), which has 203 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which creatine monohydrate is the first listed.
NCT00070993 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00070993 about?
NCT00070993 is a clinical study titled "Creatine for the Treatment of Amyotrophic Lateral Sclerosis". Creatine is a naturally occurring chemical involved in the production of energy in muscle. Abnormalities in creatine have been linked to the progression of degenerative neuromuscular diseases such as amyotrophic lateral sclerosis (ALS, or Lou Gehrig's Disease). This study will test whether taking cr...
What is the current status of trial NCT00070993?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 110 participants. The study started on 2002-12. Estimated completion is 2006-05.
What interventions are being tested in trial NCT00070993?
The interventions under investigation include: creatine monohydrate (DRUG).
Who is sponsoring clinical trial NCT00070993?
This trial is sponsored by National Center for Complementary and Integrative Health (NCCIH), which has 203 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.